Sector: Health Care
Director information for DEFINIUM THERAPEUTICS INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Andreas Krebs | Vice Board Chair; Vice Chair of the Board | 68 | ["Former President and Executive board member of Wyeth Corporation","Heads family-owned investment company, Longfield Invest GmbH","Board member of AHW GmbH","Former board member of IDT Biopharma","Former industry advisor for Nordic Capital","member of the board of AHW GmbH","Former member of the board of IDT Biopharma"] | ["Nominating and Corporate Governance Committee","Audit Committee"] | 2026 |
| Carol A. Vallone | Board Chair; Chair of the Board | 69 | ["Chair of the board of trustees of McLean Hospital (affiliate of Harvard Medical School)","Member of the board of trustees of Mass General Brigham","Chair of the board of directors of RiaHealth and CrowdComfort","Board member of Bain Capital double impact portfolio company, Arosa; and Hightop Health","Former board member of Cresco Labs, Inc.","Industry Advisor for Berkshire Partners","Advisory Board member for Longitude Capital","Chair of the Board of the Company","Industry advisor for Berkshire Partners","advisory board member for Longitude Capital"] | ["Compensation Committee","Audit Committee","board of trustees of McLean Hospital","finance committee for Mass General Brigham","compensation committee of Cresco Labs, Inc.","executive committee of Cresco Labs, Inc.","board of Bain Capital Double Impact portfolio company, Arosa","board of HighTop Health","board of SV Health Investors’ portfolio company, Ria Health","board of CrowdComfort"] | 2026 |
| David Gryska | Chair of Audit Committee and Audit Committee Financial Expert; Member of the Board | 70 | ["Former Chief Financial Officer of Incyte Corporation","Former Chief Financial Officer of Celgene Corporation","Member of the board and the audit committee of Forte Biosciences, Inc.","Former Executive Vice President and Chief Financial Officer of Incyte Corporation","Former member of the boards of directors of GW Pharmaceuticals plc, Aerie Pharmaceuticals Inc. and Seagen Inc."] | ["Audit Committee","audit committee of Forte Biosciences, Inc."] | 2026 |
| Robert Barrow | Chief Executive Officer | 37 | ["Former Chief Development Officer of Definium","Former Director of Drug Development & Discovery at Usona Institute","Former Chief Operating Officer and Board Director of Olatec Therapeutics LLC","Pharmaceutical executive and clinical pharmacologist with over a decade of experience leading drug development programs in a variety of disease areas"] | [] | 2026 |
| Roger Adsett | Director; Member of the Board | 57 | ["Chief Operating Officer of Insmed Inc.","Former member of the board and the audit committee of Landos Biopharma, Inc.","Chief Operating Officer and Chief Commercial Officer of Insmed Inc.","Former member of the board of Landos Biopharma, Inc."] | [] | 2026 |
| Roger Crystal | Chair of Nominating and Corporate Governance Committee and member of Compensation Committee; Member of the Board | 49 | ["Chief Executive Officer of FoldLogic Bio","Chief Executive Officer and Chairman of W12 Therapeutics","Chief Executive Officer of Crystal Advisory LLC","Senior Advisor to Oaktree Capital","Former President, Chief Executive Officer and board member of Opiant Pharmaceuticals, Inc.","Lead inventor of NARCAN Nasal Spray","Former President, Chief Executive Officer and member of the board of Opiant Pharmaceuticals, Inc."] | ["Nominating and Corporate Governance Committee","Compensation Committee"] | 2026 |
| Suzanne Bruhn | Chair of Compensation Committee and member of Nominating and Corporate Governance Committee; Member of the Board | 62 | ["Chief Executive Officer of the Charcot-Marie-Tooth Association (CMTA)","Board member of Pliant Therapeutics, Inc.","Board member of Travere Therapeutics, Inc.","Former member of the board of Vigil Neuroscience, Inc.","Member of boards of directors of Pliant Therapeutics, Inc. and Travere Therapeutics, Inc."] | ["Compensation Committee","Nominating and Corporate Governance Committee"] | 2026 |
